Bivalirudin

Bivalirudin is a direct thrombin inhibitor given by vein as an anticoagulant. The US label read lists one use: as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI (percutaneous coronary intervention)), including patients with heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia and thrombosis syndrome (HITTS). The label says it binds thrombin directly and reversibly.

Also called Angiomax

  • Drug
  • In this atlas

Overview

Technical summary

RxNorm ingredient 60819; UNII TN9BEX005G. MeSH has no descriptor for bivalirudin (an exact-label lookup and a contains lookup on 2026-11-09 returned none), so no MeSH identifier is recorded. Classes: Direct Thrombin Inhibitor and Anti-coagulant (FDA established pharmacologic classes, RxClass). The label read is the Civica, Inc. label for bivalirudin for injection, application NDA020873 (the application of the brand product Angiomax), effective 2025-09-10 in openFDA. openFDA returned no brand-named Angiomax record. Other bivalirudin labels were not read. This page records label indications and the class only: no trial result and no dose is given.

Trials at a glance

The figures count the 13 registry trials in this atlas that name this drug or a product that contains it. Trials that use another name for it are not counted.

Trials
13
Phase 3 or 4
13
Recruiting
0
Regulatory decisions
0
Trials by phase (rows) and registry status (columns)
PhaseCompletedTerminatedUnknown statusAll statuses
Phase 32114
Phase 45049
All phases71513

Conditions these trials study

Sponsors with the most trials

The lead sponsor of each trial, as the registry names it.

And 6 more.

About this drug

Level
Substance
Mechanism
The label says bivalirudin binds thrombin directly, at its catalytic site and its anion-binding exosite, and that the binding is reversible.

Claims and evidence

Context People for whom the US label of bivalirudin for injection lists an indication: anticoagulation during percutaneous coronary intervention, including heparin-induced thrombocytopenia

Recipient
Recipient not specified
Population
Patients described in the indications section of the label. The label passage read does not state an age range.
Care setting
Prescription medicine, as described in the US label
Geography
United States (label of the US Food and Drug Administration)
Life stage
Not stated in the label passage read
Gestational age
Not reported
Postnatal age
Not reported
Follow-up
Not applicable (label statement)
Eligibility: 2 inclusion criteria; exclusion criteria not stated
Included
Excluded
None stated
  • Description Evidence stage not applicable Certainty not assessed

    The US label of bivalirudin for injection, in the Civica, Inc. version dated 2025-09-10 in openFDA (application NDA020873), describes bivalirudin as a direct thrombin inhibitor and lists it for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI), including patients with heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia and thrombosis syndrome (HITTS).

    Applies to Recipient not specified People for whom the US label of bivalirudin for injection lists an indication: anticoagulation during percutaneous coronary intervention, including heparin-induced thrombocytopenia

    Certainty method
    Not assessed
    Limitations
    This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label has no boxed warning section in openFDA; contraindications, doses, interactions and other warnings were not read. The atlas has no page for heparin-induced thrombocytopenia, so no edge to it is recorded. Labels differ between sponsors and change over time. openFDA's own disclaimer says not to rely on it for decisions about medical care.
    Last checked
    2026-11-09
    Next evidence check due
    Not scheduled
    Sources and citations (2)
    1. Supports openFDA drug label record for Bivalirudin for Injection, Civica, Inc. label (application NDA020873): indications and mechanism

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 19a4afc5-151d-4d3c-bfef-48aa8797d695 (manufacturer Civica, Inc., application NDA020873), returned on 2026-11-09. The label text is dated 2025-09-10 (effective_time). An openFDA brand-name search for ANGIOMAX returned no record. Fourteen other bivalirudin labels (several sponsors, generic and 505(b)(2) products) were listed and not read.

      Locator
      results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE (highlights)
      How it applies
      Label passage quoted in the research quote table (LB-04).
      Retrieved
      Source effective date
      2025-09-10
      Source state
      Current
      Version fingerprint
      f0c2c42a75f215c009acc029d902785ae6f38dd5fac72d6557571d71259a64d8
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Background openFDA drug label record for Bivalirudin for Injection, Civica, Inc. label (application NDA020873): indications and mechanism

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 19a4afc5-151d-4d3c-bfef-48aa8797d695 (manufacturer Civica, Inc., application NDA020873), returned on 2026-11-09. The label text is dated 2025-09-10 (effective_time). An openFDA brand-name search for ANGIOMAX returned no record. Fourteen other bivalirudin labels (several sponsors, generic and 505(b)(2) products) were listed and not read.

      Locator
      results[0].effective_time
      How it applies
      Effective date of the label text read, 20250910.
      Retrieved
      Source effective date
      2025-09-10
      Source state
      Current
      Version fingerprint
      f0c2c42a75f215c009acc029d902785ae6f38dd5fac72d6557571d71259a64d8
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.

FDA label

The FDA label of the application holder, as the openFDA label dataset holds it, for the products that contain this drug.

ANGIOMAX

No label from the application holder was found in the openFDA label dataset for application NDA020873. This page does not show another labeler's label in its place.

ANGIOMAX RTU

No label from the application holder was found in the openFDA label dataset for application NDA211215. This page does not show another labeler's label in its place.

BIVALIRUDIN IN 0.9% SODIUM CHLORIDE

No label from the application holder was found in the openFDA label dataset for application NDA208374. This page does not show another labeler's label in its place.

FDA decisions timeline

The regulatory decisions of the FDA that this atlas holds for this drug and the products that contain it, oldest first. Each links to its full record.

  1. Approval NDA020873 ANGIOMAX
  2. Supplemental approval NDA020873 ANGIOMAX
  3. Supplemental approval NDA020873 ANGIOMAX
  4. Approval NDA208374 BIVALIRUDIN IN 0.9% SODIUM CHLORIDE
  5. Approval NDA211215 ANGIOMAX RTU

Registry records

Assembled by a program from ClinicalTrials.gov and openFDA. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.

Registry products 3

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 2 efficacy supplement approvals on record.

    ProductNDA020873

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.

    ProductNDA208374

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.

    ProductNDA211215

Registry trials 13

Record details

Record id
cardio:bivalirudin
Content hash
cad976b70bd8828393afa360ab43693bca394a20e8f4d19c3984abe34930c1ae